Latest Aortic valve replacement Stories
MINNEAPOLIS, Oct. 30 /PRNewswire-FirstCall/ -- ATS Medical, Inc. , manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced it has received U.S. Food and Drug Administration (FDA) approval for the ATS 3f(R) Aortic Bioprosthesis. (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO) This is the Company's first entry into the $400-plus Million U.S. tissue valve market. Based on the precept that 'Form Follows Function', the ATS 3f Aortic...
CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValving(R) System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries. During the Monday Transcatheter Aortic Valve Replacement sessions at TCT 2008 meeting in Washington, D.C., CoreValve investigators and...
NEW YORK, Sept. 25, 2008 (GLOBE NEWSWIRE) -- In the wake of Bayer's announcement that it pulled its controversial heart surgery drug Trasylol from the market after a Canadian study suggested that its use increased surgical complications and death rates, nationally known plaintiff's advocates Napoli Bern Ripka & Associates, LLP has filed another lawsuit seeking damages on behalf of a heart surgery patient who, after being administered Trasylol (Aprotonin), experienced renal failure requiring...
By HOLLOWAY, Bruce A debilitating heart condition means Alan Miller, 79, finds it a struggle to walk to his letterbox and back. The Otorohanga man suffers from aortic stenosis - a condition where the main outflow valve from the heart thickens and does not open fully - it's the most common heart valve disease in the Western world. But, although that's been frustrating for a bloke who played cricket until he was 64, and remains a keen golfer, it was all due to change today. Mr Miller was...
CoreValve (www.corevalve.com) announced today that an Australia/New Zealand-focused clinical evaluation of its proprietary percutaneous ReValving(R) System, which features a porcine pericardium valve mounted in a self-expanding frame, was initiated last week. The first four procedures using the CoreValve ReValving(R) System were performed in two days by John Ormiston, M.D., Medical Director at Mercy Hospital in Auckland, New Zealand. "With the CoreValve ReValving system, a new heart...
By Greg Mellen LONG BEACH - When David Kem of Long Beach volunteered to help organize a benefit for a Cambodian girl who had been brought to the United States for life-altering open-heart surgery, it was because it seemed the right thing to do. He certainly didn't expect anything in return. "I just heard about her story and followed it in the paper and thought, 'Wouldn't it be great to help?"' Kem says. Now, Kem may have received a gift beyond payment. A week or so after the benefit, in...
Hansen Medical, Inc. (NASDAQ: HNSN) announced today that it has signed a definitive agreement to acquire AorTx, Inc., of Redwood City, Calif. AorTx is an early stage developer of "percutaneous" or catheter-based valve technology. This acquisition will allow Hansen Medical to leverage its Sensei(TM) Robotic Catheter system, which is currently marketed for electrophysiology procedures, into the rapidly developing market for percutaneous heart valve therapy. "It has been a core element of our...
